HK Stock Market Move | INSILICO (03696) surged more than 7%, expected to turn losses into profits and earn up to $39.5 million in the first half of the year.

INSILICO (03696) rose more than 7%, as of the time of writing, it rose by 7.08% to 39.62 Hong Kong dollars, with a trading volume of 166 million Hong Kong dollars. On the news front, INSILICO announced a profit increase, expecting to record revenue of approximately 1.025 billion to 1.065 billion US dollars in the first half of 2026, a year-on-year increase of about 272.7% to 287.3%; net profit is expected to be approximately 33.5 million to 39.5 million US dollars, turning losses into profit; adjusted net profit is expected to be approximately 45.5 million to 51.5 million US dollars. The significant growth in performance is attributed to the positive results achieved by the company in promoting global licensing, joint development, and research cooperation in the first half of 2026. It is reported that since 2026, INSILICO has successively reached pipeline licensing or research cooperation agreements with companies such as Shiseido, Shanghai Fosun Pharmaceutical subsidiary Hengtai Biology, Qilu Pharmaceutical, CMS, Yuanye Biology, Lilly, and SK Biopharmaceuticals, with a total of nearly 7 billion US dollars in new business expansion.